AGP Picks
View all

Clinical trial services market seen reaching $95.23 billion by 2030

2 hours ago
Clinical trial services market seen reaching $95.23 billion by 2030
By AI, Created 00:30 UTC, Nov 19, 2026, AGP -

The clinical trial services market is projected to grow from $56.17 billion in 2025 to $95.23 billion by 2030, driven by decentralized trials, patient recruitment pressure and broader use of analytics. North America held the largest share in 2025 and is expected to be the fastest-growing region through the forecast period.

Why it matters: - Clinical trial services are becoming more central to drug and device development as trials get more complex and more globally distributed. - The market outlook points to sustained demand for outsourcing, regulatory support and data-driven trial operations. - A larger market signals more spending on the infrastructure that helps bring treatments to patients faster.

What happened: - The Business Research Company said the clinical trial services market is expected to rise from $56.17 billion in 2025 to $62.57 billion in 2026. - The company projects the market will reach $95.23 billion by 2030, implying an 11.1% CAGR from 2026 to 2030. - North America held the largest share of the market in 2025 and is projected to be the fastest-growing region during the forecast period. - The report covers North America, Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The release also points readers to a free sample of the report and the full market report.

The details: - Clinical trial services include support for trial design, management and analysis. - The services cover patient recruitment, data collection, monitoring, regulatory submissions, statistical evaluation and final reporting. - The market's recent growth reflects higher pharmaceutical R&D spending, broader global trial pipelines, more complex regulatory requirements, more studies across multiple therapeutic areas and greater use of CRO expertise. - The forecast through 2030 is tied to decentralized and hybrid clinical trials, better patient recruitment, more use of real-world evidence, wider adoption of advanced analytics and demand for faster trial timelines. - The report expects more outsourcing of end-to-end clinical trial services, greater use of data-driven monitoring, broader adoption of risk-based monitoring, more patient-centric trial designs and stronger regulatory compliance support. - Personalized medicine is a major demand driver because it relies on targeted treatments built around genetic, environmental and lifestyle factors. - Advances in genomic technologies, targeted therapies, AI, biomarkers and real-world data are supporting that shift. - In February 2024, the Personalized Medicine Coalition said the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six approvals in 2022.

Between the lines: - The forecast suggests sponsors are shifting trial execution toward faster, more flexible models that can handle tighter timelines and heavier compliance burdens. - Growth in personalized medicine also raises the need for trial services that can manage biomarker-driven studies and smaller, more specialized patient populations. - North America's lead likely reflects its concentration of pharma activity, trial infrastructure and regulatory capabilities. - The report's emphasis on analytics and monitoring indicates that efficiency, not just scale, is becoming a competitive requirement.

What's next: - The Business Research Company expects decentralized trial models, hybrid designs and advanced analytics to shape the market through 2030. - More demand should flow to CROs and other providers that can offer integrated trial operations, compliance support and patient recruitment solutions. - The company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis. - More information is available through the company's LinkedIn page.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Latin America News Network

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Latin America News Network

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.